2026年BPC-157:法律状况,FDA类别,卖家犯错误

在美国是否合法购买或销售BPC-157?

No federal statute criminalizes simple possession of BPC-157, but that is a different question from whether a seller can lawfully market it for human use, and the answer there is no. Under 21 CFR 201.128, a product's intended use is judged by 'labeling claims, advertising matter, or oral or written statements' and by 'the circumstances surrounding the distribution of the article,' per the Cornell Legal Information Institute's text of the rule — meaning a seller's marketing controls the legal classification, not a disclaimer printed below it.

根据21 U.S.C. 321 ((ff) 1),补充剂必须含有维生素,矿物质,草药,氨基酸或类似的饮食物质 封闭列表 合成,非食品酸不适合,根据康奈尔法律信息研究所的法定文本. 卖给人用,并且相同的行为链关闭了Gram Peptides适用于:未经批准的新药,违反联邦法律.

为什么FDA把BPC-157列入503A类2?

FDA placed BPC-157 on the 503A Category 2 list because its own review found the compound risky to compound, not because Congress or a court ruled on it. Category 2 comprises bulk substances FDA identified as presenting significant safety risks in compounding, and for BPC-157 the agency's stated finding was that it 'may pose risk for immunogenicity' with 'no, or only limited, safety-related information,' per FDA's bulk drug substances safety-risk page.

That finding, not any court decision or new statute, is why pharmacies compounding BPC-157 faced restrictions for years. Category 2 status functioned as an FDA advisory that the safety profile was too thin to support routine compounding. The listing said nothing about recreational legality — it addressed only whether a 503A pharmacy could use BPC-157 as a starting ingredient, and FDA answered no.

2026年化重新分类实际上改变了什么?

The 2026 reclassification removed BPC-157 from Category 2, but it did not resolve FDA's safety concerns or open a compounding pathway. Effective April 22, 2026, BPC-157 moved to FDA's 'nominated but withdrawn' table because the original nominators withdrew their submissions — a procedural exit, not a safety exoneration — and FDA still publishes the same immunogenicity concern it cited while the substance sat in Category 2, per its current bulk drug substances page.

销售人员读到此取消,因为FDA然地清除了BPC-157,但相反的论点更好地抵制记录.在2026年5月14日的更新中,第2类仅列出了六种物质 (化,皮,基氧化,ibutamoren mesylate, kisspeptin-10, quinacrine HCl用于子宫内使用),而BPC-157根本不出现在任何一类1,2或3类.每类的缺席不是绿色灯;它甚至消除了正在候选的狭窄的类型1.

药店现在可以提供BPC-157吗?

没有,今天503A药店不能合法发放复合BPC-157,而二类撤销并没有改变这一点.503A (b) (1) (a) (a) 允许只使用符合USP/NF单一图书的大量物质,是FDA批准的药品成分,或出现在503A批量清单中.

实际效果是,药店现在的法律基础比它可能认为,当BPC-157提名还在待定时.FDA的框架对取消作为中立,但对于一个药店考虑是否填写BPC-157订单,中立不是许可.FDA对大量物质的沉默一直意味着没有复合,不是等待绿灯.

酸-157可作为补充剂,化品或"研究"产品销售吗?

没有一个常见的三种方法可以解决:BPC-157不能合法销售为饮食补充剂,化品或标签为"研究"化学品,

The disclaimer strategy is the one sellers lean on hardest, and it is also the one FDA has rejected most bluntly in writing — a pattern laid out in why 'research use only' is not a legal shield for peptide sellers. FDA even reasoned that bundling bacteriostatic water alongside a peptide requiring reconstitution is itself evidence of human-use intent, regardless of what the label says.

2026年7月的复合顾问委员会将决定什么?

2026年7月23日至24日的药物组合咨询委员会会议通过近距离投票建议将BPC-157添加到503A批量清单中,但仅仅是为了性结肠炎的狭窄迹象,而且仅仅是作为建议.该文件,FDA-2025-N-6895,还涵盖了KPV,TB-500,MOTS-tidec,epitalon和semax,委员会投票反对添加emidel (DSIP).

根据Mintz的会议分析,咨询委员会投票不是机构的行动,FDA的科学评论者建议不要包括所有七种化物,因为缺乏临床数据或特征.该公司写道:"法律上还没有发生任何变化,因为该建议不绑定FDA.预计2027年2月将举行第二次PCAC会议,涵盖五种额外化物,直到FDA采取行动,BPC-157的成分状况与之前的部分描述不变.

果157商店或附属公司面临什么影响?

根据Gram Peptides案例,FDA的警告信件模板将BPC-157的作用机制或减肥方式副本视为不论 RUO免责声明如何证明人类使用意图的证明,暴露了任何产品页面描述了BPC-157在身体中所做的事情.

美国州监管机构正在并行行动.阿拉巴马州的总检察长于2025年11月起诉Aurora IV和Wellness因"制药级"化物索赔,获得了TRO,该公司关闭了业务,并于2026年1月为约24,000美元的赔偿金以及交付许可证和解.康涅狄格州的总检察长单独从原油化物分销商获得了18,500美元的和解,并发出了停止和退出信件,因为公司实践中药违规在减肥诊所.

Ad platforms add a fourth layer that has nothing to do with FDA at all. Meta's Unacceptable Business Practices policy bars 'deceptive or exaggerated claims about health-related benefits,' and Google's Unapproved substances policy bans products that imply they work as well as a prescription drug 'regardless of any claims of legality' — the mechanics of both are covered in peptide advertising rules for BPC-157, GLP-1s and the FDA. An account suspension can end distribution faster than any single warning letter.

快速决策检查列表

实际问题是,读者是否需要更快的证据来了解已经在VSL驱动的直接反应中发挥作用,特别是在营养品,补充剂,GLP-1,减肥,血糖以及相邻的高意向健康市场上.

对于下一个决定,最重要的是根据市场活动的例子:哪个子要测试,哪个索赔风格是风险的,哪个道结构是常见的,哪个语言市场正在移动,以及竞争对手的创意是否可能是早期,扩展或已经和.

• 如果您需要直接答案,请从TL;DR开始.
• 快速比较交易.
• 使用常见问题,以提供答案机准备的总结.
• 根据该决定,使用CTA,而不是理论,需要实时VSL和广告示例.

报道报道报道报道报道报道报道报道报道报道报道报道

广告客户在视觉创意之外所做的事情理解的环境,包括广告客户在黑帽,灰帽和白帽广告模式中,具有足够的背景.实际的区别是,用户不仅看到屏幕截图;他们正在看到VSL,广告,道,转录,UTM文本和将资产转化为决定的研究笔记.

这很重要,因为直接响应的附属公司并不属于一个清洁类别.减肥活动可能使用白帽合规广告,灰帽预登陆器,更具侵略性的VSL和围绕上和恢复设计的收购路径.有用的智能平台需要捕获这种频谱,而不是假装每一次获胜的活动都像公共品牌广告.

黑帽,白帽和多语言信号覆盖

每日英特尔在黑帽和白帽式运动中追踪模式,以便运营商能够理解市场而不盲目复制风险.白帽的例子有助于耐用性和合规性审查;黑帽和灰帽的例子揭示了压力点,子,机制和道结构,这些机制可能会推动支出,但需要在使用前仔细适应.

该目录也为全球运营商构建,VSL和广告引用涵盖14多种语言和不同的当地语法.这对于巴西,拉塔姆,欧洲,MENA,印度和非原生英语附属公司来说是一个关键优势,他们需要看到市场的相同愿望如何跨文化转化,而不是仅仅研究美国英语广告.

如何负责任地使用情报

目标是建模,而不是复制. 使用每日英特尔来了解结构:,机制,证明,要求强度,深度,提供经济学和和阶段.然后构建原创创意,审查要求,并适应角度流量来源,国家,语言和合规要求的竞选.

强大的工作流程在行动之前比较多个例子.如果同一机制在多种语言,多种广告商和多种道变体中出现,它可能是持久的市场信号.如果这个例子只出现一次或依赖于攻击性索赔,请把它视为研究线索而不是竞选模板.

• 模型结构,而不是保护的创意资产.
• 单独的白帽耐用性与黑帽说服压力.
• 比较美国英语的例子与拉塔姆,欧洲和其他语言变体.
• 通过转录和接笔来构建原始简单.
• 保持合规性审查与市场研究分开.

方法论与来源背景

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For educational pages, the supporting references should help readers verify search, crawlability, and public ad research context, especially Google helpful content guidance, Google SEO link best practices, and Meta Ad Library. Daily Intel then adds the direct-response interpretation layer so the page explains what the signal means for actual affiliate research decisions.

For deeper evaluation, continue through Nutra niche intelligence directory, Immune Claims: Brand, Retailer and Officers All Paid, FDA Blessed "Alleviates Bloating." Here Is the List., A Probiotic Brand Was Sunk by Its Own Bibliography, Occasional or Chronic: The Word That Decides, and What is a VSL?. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.